Zavante raises $45M to bring antibiotic fosfomycin to U.S.
So why is Zavante brushing the dust off fosfomycin? After all, it was actually first tested in the 1960s in Spain, but had been ruled as fairly ineffective in comparison to other antibiotics on the market.